combine@alvar.ug

Updating vital status by tracking in the community among patients with epidemic Kaposi sarcoma who are lost to follow-up in sub-Saharan Africa

Updating vital status by tracking in the community among patients with epidemic Kaposi sarcoma who are lost to follow-up in sub-Saharan Africa

Show simple record

dc.contributor.author Semeere, Aggrey
dc.contributor.author Freeman, Esther
dc.contributor.author Wenger, Megan
dc.contributor.author Glidden, David
dc.contributor.author Bwana, Mwebesa
dc.contributor.author Kanyesigye, Micheal
dc.contributor.author Asirwa, Fredrick Chite
dc.contributor.author Rotich, Elyne
dc.contributor.author Busakhala, Naftali
dc.contributor.author Oga, Emmanuel
dc.contributor.author Jedy-Agba, Elima
dc.contributor.author Kwaghe, Vivian
dc.contributor.author Iregbu, Kenneth
dc.contributor.author Adebamowo, Clement
dc.contributor.author Jaquet, Antoine
dc.contributor.author Dabis, Francois
dc.contributor.author Phiri, Sam
dc.contributor.author Bohlius, Julia
dc.contributor.author Egger, Matthias
dc.contributor.author Yiannoutsos, Constantin T.
dc.contributor.author Wools-Kaloustian, Kara
dc.contributor.author Martin, Jeffrey
dc.date.accessioned 2021-01-01T21:57:57Z
dc.date.available 2021-01-01T21:57:57Z
dc.date.issued 2017
dc.identifier.issn 1471-2407
dc.identifier.uri http://combine.alvar.ug/handle/1/48084
dc.description.abstract Background: Throughout most of sub-Saharan Africa (and, indeed, most resource-limited areas), lack of death registries prohibits linkage of cancer diagnoses and precludes the most expeditious approach to determining cancer survival. Instead, estimation of cancer survival often uses clinical records, which have some mortality data but are replete with patients who are lost to follow-up (LTFU), some of which may be caused by undocumented death. The end result is that accurate estimation of cancer survival is rarely performed. A prominent example of a common cancer in Africa for which survival data are needed but for which frequent LTFU has precluded accurate estimation is Kaposi sarcoma (KS). Methods: Using electronic records, we identified all newly diagnosed KS among HIV-infected adults at 33 primary care clinics in Kenya, Uganda, Nigeria, and Malawi from 2009 to 2012. We determined those patients who were apparently LTFU, defined as absent from clinic for >= 90 days at database closure and unknown to be dead or transferred. Using standardized protocols which included manual chart review, telephone calls, and physical tracking in the community, we attempted to update vital status amongst patients who were LTFU. Results: We identified 1222 patients with KS, of whom 440 were LTFU according to electronic records. Manual chart review revealed that 18 (4.1%) were classified as LFTU due to clerical error, leaving 422 as truly LTFU. Of these 422, we updated vital status in 78%; manual chart review was responsible for updating in 5.7%, telephone calls in 26%, and physical tracking in 46%. Among 378 patients who consented at clinic enrollment to be tracked if they became LTFU and who had sufficient geographic contact/locator information, we updated vital status in 88%. Duration of LTFU was not associated with success of tracking, but tracking success was better in Kenya than the other sites. Conclusion: It is feasible to update vital status in a large fraction of patients with HIV-associated KS in sub-Saharan Africa who have become LTFU from clinical care. This finding likely applies to other cancers as well. Updating vital status amongst lost patients paves the way towards accurate determination of cancer survival.
dc.description.sponsorship National Institute Of Allergy And Infectious Diseases (NIAID)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
dc.description.sponsorship Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
dc.description.sponsorship National Institute On Drug Abuse (NIDA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)
dc.description.sponsorship National Cancer Institute (NCI)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
dc.description.sponsorship National Institute of Mental Health (NIMH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)
dc.description.sponsorship National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01 AI096299, U01 AI069919, U01 AI069924, D43 CA153717, U54 CA190153, P30 AI027763, T32 AR007098]
dc.description.sponsorship Dermatology Foundation
dc.description.sponsorship President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development (USAID)United States Agency for International Development (USAID) [AID-623-A-12-0001]
dc.description.sponsorship NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, D43CA153717, U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, D43CA153717, U54CA190153, U54CA190153, U54CA190153, U54CA190153, U54CA190153, D43CA153717, U54CA190153, U54CA190153, U54CA190153, D43CA153717, U54CA190153, U54CA190153] Funding Source: NIH RePORTER
dc.description.sponsorship NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [P30AI027763, U01AI069911, P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI069924, P30AI027763, U01AI069919, P30AI027763, U01AI069911, P30AI027763, P30AI027763, U01AI069924, U01AI069911, P30AI027763, P30AI027763, U01AI069919, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI096299, P30AI027763, P30AI027763, P30AI027763, U01AI069924, P30AI027763, U01AI069919, P30AI027763, U01AI096299, U01AI069911, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI069924, P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI069911, P30AI027763, P30AI027763, P30AI027763, U01AI069919, U01AI069919, P30AI027763, P30AI027763, U01AI096299, P30AI027763, P30AI027763, U01AI096299, U01AI069924, U01AI069924, P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI069911, U01AI069924, U01AI069911, P30AI027763, P30AI027763, U01AI069924, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI069911, P30AI027763, U01AI069919, P30AI027763, P30AI027763, U01AI069911, P30AI027763, U01AI069919, P30AI027763, U01AI096299, P30AI027763, P30AI027763, P30AI027763, U01AI069924, U01AI069911, U01AI096299, U01AI069924, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI069924, P30AI027763, U01AI069911, P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI096299, P30AI027763, U01AI069911, U01AI069924, U01AI069919, U01AI096299, P30AI027763, P30AI027763, U01AI069911, U01AI069911, P30AI027763, P30AI027763, U01AI096299, P30AI027763, U01AI069911, P30AI027763, P30AI027763, U01AI069911, U01AI069919, U01AI069924, P30AI027763, U01AI096299, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI069924, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI069919, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI096299, P30AI027763, P30AI027763, P30AI027763, U01AI069919, U01AI096299, U01AI069911, P30AI027763, P30AI027763, U01AI069924, P30AI027763, P30AI027763, U01AI069919, P30AI027763, U01AI069924, P30AI027763, P30AI027763, U01AI069919, P30AI027763, U01AI069919, P30AI027763, U01AI069911, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI069911, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI069911, P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI069924, U01AI069924, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI069919, U01AI069924, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI096299, U01AI096299, U01AI069924, U01AI069911, U01AI069919, P30AI027763, U01AI069911, U01AI096299, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, P30AI027763, U01AI069911, P30AI027763, P30AI027763] Funding Source: NIH RePORTER
dc.description.sponsorship NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098, T32AR007098] Funding Source: NIH RePORTER
dc.language English
dc.publisher BIOMED CENTRAL LTD
dc.relation.ispartof BMC Cancer
dc.subject Loss To Follow-Up
dc.subject Tracking
dc.subject Tracing
dc.subject Updating Vital Status
dc.subject Survival
dc.subject Mortality
dc.subject Kaposi Sarcoma
dc.subject Hiv/Aids
dc.subject Cancer
dc.subject Resource-Limited Settings
dc.subject Sub-Saharan Africa
dc.title Updating vital status by tracking in the community among patients with epidemic Kaposi sarcoma who are lost to follow-up in sub-Saharan Africa
dc.type Article
dc.identifier.isi 000408853600001
dc.identifier.doi 10.1186/s12885-017-3549-1
dc.identifier.pmid 28865422
dc.publisher.city LONDON
dc.publisher.address 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
dc.identifier.volume 17
dc.subject.wc Oncology
dc.subject.sc Oncology
dc.description.oa DOAJ Gold
dc.description.oa Green Published
dc.description.oa Green Accepted
dc.description.pages 11
dc.subject.kwp Antiretroviral Therapy
dc.subject.kwp Cancer Incidence
dc.subject.kwp Survival
dc.subject.kwp Uganda
dc.subject.kwp Outcomes
dc.subject.kwp Cohort
dc.subject.kwp Registration
dc.subject.kwp Population
dc.subject.kwp Zimbabwe
dc.subject.kwp Kampala
dc.identifier.articleno 611
dc.description.affiliation Makerere Univ, Coll Hlth Sci, Infect Dis Inst, Kampala, Uganda
dc.description.affiliation Univ Calif San Francisco, San Francisco, CA 94143 USA
dc.description.affiliation Massachusetts Gen Hosp, Boston, MA 02114 USA
dc.description.affiliation Mbarara Univ Sci & Technol, Mbarara, Uganda
dc.description.affiliation Indiana Univ, Indianapolis, IN 46204 USA
dc.description.affiliation Moi Univ, AMPATH, Eldoret, Kenya
dc.description.affiliation Inst Human Virol, Abuja, Nigeria
dc.description.affiliation Univ London, London Sch Hyg & Trop Med, London, England
dc.description.affiliation Univ Abuja, Teaching Hosp, Gwagwalada, Nigeria
dc.description.affiliation Natl Hosp Abuja, Abuja, Nigeria
dc.description.affiliation Univ Bordeaux, INSERM, U1219, Bordeaux, France
dc.description.affiliation Univ Bordeaux, INSERM, ISPED, Bordeaux, France
dc.description.affiliation Lighthouse Trust Clin, Lilongwe, Malawi
dc.description.affiliation Univ Bern, Bern, Switzerland
dc.description.email asemeere@gmail.com
dc.description.corr Semeere, A (corresponding author), Makerere Univ, Coll Hlth Sci, Infect Dis Inst, Kampala, Uganda.; Semeere, A (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.
dc.description.orcid Adebamowo, Clement/0000-0002-6571-2880
dc.description.orcid Oga, Emmanuel/0000-0002-0744-5681
dc.description.orcid Iregbu, Kenneth/0000-0003-4780-0497
dc.description.orcid DABIS, FRANCOIS/0000-0002-1614-8857
dc.description.orcid Egger, Matthias/0000-0001-7462-5132
dc.description.orcid Glidden, David/0000-0001-5888-1419
dc.description.orcid Freeman, Esther/0000-0001-7751-9466


This record appears in the collections of the following institution(s)

Show simple record

Search Entire Database


Browse

My Account